GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » DeferredTaxAndRevenue

GUTS (Fractyl Health) DeferredTaxAndRevenue : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Fractyl Health's current deferred tax and revenue for the quarter that ended in Mar. 2025 was $0.00 Mil.

Fractyl Health DeferredTaxAndRevenue Historical Data

The historical data trend for Fractyl Health's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health DeferredTaxAndRevenue Chart

Fractyl Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.53 - - - -

Fractyl Health Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fractyl Health DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Fractyl Health's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fractyl Health Business Description

Traded in Other Exchanges
N/A
Address
3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.